Explore

Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed

Ori Biotech and ImmuXell Partner to Advance Cell Therapy with First Patient Dosed
Trendline Trendline
Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment
Trendline Trendline
Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting
Trendline Trendline
Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors
Trendline Trendline
Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia
Trendline Trendline
Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies